Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Corresponding author: Pa-thai Yenchitsomanus
E-mail: pathai.yen@mahidol.ac.th; ptyench@gmail.com
Received 7 April 2026 Revised 17 April 2026 Accepted 21 April 2026 ORCID ID: http://orcid.org/0000-0001-9779-5927 https://doi.org/10.33192/smj.v78i5.281440
All material is licensed under terms of the Creative Commons Attribution 4.0 International (CC-BY-NC-ND 4.0) license unless otherwise stated.
ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapy and CD3-directed bispecific T-cell engagers (BiTEs) have transformed cancer immunotherapy, particularly for relapsed or refractory hematologic malignancies. However, CAR T-cell therapy remains constrained by complex genetic engineering, individualized manufacturing, specialized infrastructure, high cost, limited accessibility, and treatment-related toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). In contrast, soluble BiTEs frequently require repeated dosing or continuous infusion because of their short serum half-life and may also induce CRS and neurotoxicity. To address these limitations, our research group at the Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT) developed bispecific protein engager (BiPE)–armed T cells (BATs), a non-genetically modified and adaptable platform that combines BiPE-mediated tumor targeting with the intrinsic cytotoxic activity of activated T cells. This review positions BATs within the broader evolution of cancer immunotherapy—including monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), CAR T cells, bispecific antibodies (BsAbs), and BiTEs—and summarizes their structure and mechanism of action. BATs mediate major histocompatibility complex (MHC)-independent T-cell activation, promote immune synapse formation, and enable efficient tumor cell lysis. Clinical studies of bispecific antibody–armed T cells (BsAb-Ts), the closest clinical analogs of BATs, demonstrate feasibility, a consistent absence of dose-limiting toxicities (DLTs), and preliminary biological and clinical activity. Building on this foundation, next-generation BAT platforms targeting tumor-associated antigens and immune checkpoint molecules—including BCMA, CD138, integrin αvβ6, and PD-L1—have shown promising preclinical activity in multiple myeloma, breast cancer, and cholangiocarcinoma. Collectively, BATs represent a flexible, scalable, and potentially safer platform for next-generation precision T-cell immunotherapy.
INTRODUCTION
Cancer comprises heterogeneous diseases driven by dysregulated proliferation, invasion, and metastasis, ultimately causing organ failure and death if untreated. At the molecular level, oncogenesis arises from the progressive accumulation of genomic and epigenetic alterations that confer hallmark capabilities, including immune evasion.1 Globally, cancer accounted for approximately 20 million new cases and 9.7 million deaths in 2022, and demographic shifts are projected to increase annual incidence substantially to 35 million new cases by 2050, disproportionately affecting low- and middle-income countries where access to effective prevention and therapies remains limited.2,3 Immune surveillance can eliminate transformed cells; however, antitumor immunity is often compromised by aging, immunosuppression, and tumor-mediated evasion mechanisms, including the expression of immune checkpoint proteins.4 These insights form the foundation of modern immunotherapy, which aims to restore, amplify, or redirect immune responses to achieve durable tumor control.
The development of cancer immunotherapy has progressed through a series of pivotal milestones. Early
observations in the late 19th century by William B. Coley demonstrated that bacterial infections could induce tumor regression, leading to the development of “Coley’s toxins,” which stimulate antitumor immune responses.5 This was followed by the identification of tumor antigens and advances in monoclonal antibody technology in the 1970s–1990s, enabling targeted therapies such as rituximab. The discovery of immune checkpoint pathways, particularly CTLA-4 and PD-1, led to the development of checkpoint inhibitors that revolutionized cancer treatment by overcoming tumor-induced immune suppression.4,6 Immunotherapy has expanded from therapeutic monoclonal antibodies to antibody-drug conjugates (ADCs), vaccines, and adoptive cell transfer (ACT). ACT approaches, including tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cells, enable ex vivo expansion and/or functional programming of immune cells for enhanced tumor recognition and cytotoxicity.7,8 CAR T-cell therapy has achieved high response rates in several hematologic malignancies, establishing immune cell redirection as a powerful paradigm.8-10 Together, these sequential breakthroughs have transformed immunotherapy into a central pillar of modern oncology.
Therapeuticmonoclonalantibodies(mAbs)wereamong the earliest widely adopted targeted immunotherapies. Their specificity enables selective targeting with reduced off-target damage, and mechanisms include blockade of oncogenic signaling, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and immune checkpoint modulation.11 Antibody-drug conjugates (ADCs) extend mAb functionality by linking a tumor-targeting antibody to a potent cytotoxic payload. After binding and internalization, payload release can kill tumor cells while reducing systemic exposure compared with conventional chemotherapy.12,13
Chimeric antigen receptor (CAR) T-cell therapy enables patient-derived T cells to recognize and kill tumor cells in a major histocompatibility complex (MHC)-independent manner. First-generation CARs fused an antibody-derived single-chain variable fragment (scFv) to CD3ζ but showed limited persistence and activity, prompting iterative improvements.8,9 Second-generation CARs incorporate one costimulatory domain (e.g., CD28 or 4-1BB) and underpin most approved products, while
later-generation constructs add signaling modules and/ or inducible payloads to enhance function and modulate the tumor microenvironment.14
Our research group developed a stepwise CAR generation platform (CAR4, CAR5, and CAR6) (Fig 1), first in hematologic malignancies and then in solid tumors. In B-cell malignancies, CD19-CAR4 T cells incorporating CD28, 4-1BB (CD137), and CD27 costimulatory domains demonstrated potent antigen-specific cytotoxicity against CD19-positive leukemia/lymphoma cells with preserved proliferative capacity and reduced inflammatory cytokine production, supporting improved safety and persistence.15 Fifth-generation CAR5 designs were engineered to overcome checkpoint suppression via local secretion of anti-PD-L1 scFv, enabling effective killing of CD19-positive/PD-L1high leukemia cells and restoring activity under PD-L1-mediated inhibition.16,17 Translating to solid tumors, CAR4 T cells targeting CD133 and MUC1 in cholangiocarcinoma and FRα and Trop2 in breast cancer showed strong antigen-dependent cytotoxicity and T helper 1-type effector responses, including in three-dimensional spheroid models.18-21 Incorporation of checkpoint blockade in CAR5 constructs (e.g., BCMA-CAR5; αvβ6-CAR5, FRα-CAR5) enhanced cytotoxicity against
Fig 1. Chimeric antigen receptor (CAR) T-cell platforms developed at the Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), including fourth-generation (CAR4), fifth-generation (CAR5), and sixth-generation (CAR6) constructs. CAR4 T cells incorporate multiple costimulatory domains—CD28, 4-1BB (CD137), and CD27—linked to the CD3ζ signaling domain. CAR5 T cells retain the CAR4 architecture and are additionally engineered to secrete anti-PD-L1 single-chain variable fragments (scFv). CAR6 T cells are based on the CAR4/5 framework and are further designed to secrete anti-PD-L1 × anti-CD3 bispecific protein engagers (BiPEs).
PD-L1high targets and improved spheroid infiltration and control.17,22,23 Sixth-generation CAR6 T cells were designed to secrete an αPD-L1 × αCD3 bispecific engager, combining localized checkpoint blockade with bystander T-cell recruitment and amplifying antitumor responses in PD-L1-positive cholangiocarcinoma models.24
Clinically, CD19-targeted CAR T-cell therapies have achieved high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and large B-cell lymphomas, while BCMA-directed CAR T cells show remarkable efficacy in multiple myeloma.9,10 However, their therapeutic activity in solid tumors remains limited because of antigen heterogeneity, inadequate T-cell trafficking and infiltration, and the presence of immunosuppressive microenvironments. Consequently, next-generation strategies, including multi-target and armored CAR T cells, are actively being developed to overcome these barriers.14 Despite their substantial clinical promise, CAR T-cell therapies remain constrained by complex and time-consuming manufacturing processes, high treatment costs, and risks of CRS/ICANS that require specialized management. Standardized toxicity assessment has been improved through the consensus grading criteria established by the American Society for Transplantation and Cellular Therapy (ASTCT).25
Bispecific antibodies (BsAbs) bind two distinct antigens or epitopes and can redirect immune effector cells. A key oncologic application is T-cell redirection: one arm binds a tumor-associated antigen (TAA) and the other engages CD3, enforcing proximity, immune synapse formation, activation, and tumor lysis in an MHC-independent manner26-29 (Fig 2). Early BsAbs generated by chemical conjugation or quadroma technology were limited by heterogeneity and purification challenges. Modern engineering platforms, including knobs-into-holes, CrossMab, and common light chain/Fc engineering, support scalable production and improved stability and pharmacokinetics.30-34
Bispecific antibody-armed T cells (BsAb-Ts), regarded as first-generation “BATs”, are activated T cells transiently coated ex vivo with anti-CD3 × anti-TAA antibodies, thereby redirecting cytotoxicity without permanent genetic modification.35-40 Across early-phase studies in diverse malignancies, BsAb-Ts have shown feasibility, a reproducible safety profile with a consistent absence of dose-limiting toxicities (DLTs), and early activity signals such as immune activation, partial responses, and prolonged stable disease in subsets35-40 (Table 1).
Fig 2. Structure and mechanism of action of bispecific antibodies (BsAbs). BsAbs contain two distinct antigen-binding fragments (Fabs): one recognizing CD3 on T cells and the other targeting a tumor-associated antigen (TAA) on cancer cells. By simultaneously binding both cells, BsAbs bring T cells and tumor cells into close proximity, promoting immune synapse formation, T-cell activation, and targeted tumor cell lysis in a major histocompatibility complex (MHC)–independent manner.
TABLE 1. Summary of clinical investigations of BsAb-Ts (representative examples).35-40
Neuroblastoma, Mild CRS Partial response, GD2 osteosarcoma, Phase I/II, 3+3 160×106 (fever, chills), prolonged stable (GD2- desmoplastic escalation cells/kg/ minimal GD2- None disease, increased BATs) small round (n=12) infusion related pain IFN-γ ELISpot,
cell tumor T helper 1 cytokines35
EGFR (EGFR-
BATs)
Grade 4
astrocytoma
Phase I,
escalation plus Total 80×109 expansion cells (study-
(n=10) defined)
No CRS;
transient cytokine changes
None Induced systemic
antitumor immunity36
Metastatic Phase II 20×109 BATs
HER2 breast cancer (immune per infusion Grade 1-2 None Stable disease; (HER- (HER2-low/ consolidation) (total 80×109 infusion immune
BATs) negative) (n=32) BATs) reactions activation37
HER2+ PD-1 (HER2-
BATs)
Metastatic Phase II
castration- combination
resistant (n=14) prostate cancer
Up to 1010 BATs/infusion (twice per week for 4 weeks) in combination with
pembrolizumab
Manageable infusion
reactions
Progression-free None and overall survival
signals in subsets38
Anti-cancer
EGFR Early-phase responses, and tumor (EGFR- Pancreatic plus translational 10-40×109 Well None chemosensitization;
BATs) cancer (n=7) BATs/infusion tolerated killing of resistant
CD20
(targeting CD138-
negative
precursors)
Multiple myeloma
(peri-ASCT)
Phase Ib
(n=12)
2 doses of
1010 BATs
Safe in the peri-transplant
setting
Reduced clonogenic None cells; transferable
anti-myeloma
immunity40
cells39
CD3-engaging bispecific proteins redirect endogenous T cells toward malignant cells. “BiTE” is trademarked; here “BiPE” is used as a broader descriptor. These molecules typically comprise two linked scFvs: one binds CD3ε and the other recognizes a TAA, bridging T cells and tumor cells to drive synapse formation, T-cell activation/proliferation, and perforin/granzyme-mediated cytotoxicity in an MHC-independent manner26-28,41 (Fig 3). Clinically, blinatumomab (anti-CD19 × anti-CD3) improved outcomes in relapsed/refractory B-ALL and gained approvals including for minimal residual disease (MRD)-positive disease.42-44 In multiple myeloma, anti-BCMA × anti-CD3 bispecific antibodies such as teclistamab and elranatamab show substantial activity in relapsed/refractory settings.45,46 In solid tumors, redirection is complicated by antigen heterogeneity and on-target/off-tumor risks; however, tebentafusp (anti-gp100-derived peptide presented on HLA-A*02:01
× anti-CD3) demonstrated an overall survival benefit in metastatic uveal melanoma, validating the strategy in selected solid tumors.47,48
Despite promise, key constraints of many bispecific formats include short half-life, frequent dosing or continuous infusion requirements, and CRS/neurotoxicity risks; mitigation strategies include half-life extension, step-up dosing, and rational combinations.26-28,34
CAR T cells and soluble CD3-engaging BiTEs/ BiPEs can be highly effective but face practical and safety limitations, including manufacturing complexity and CRS/ICANS for CAR T cells, and frequent dosing and CRS/neurotoxicity for soluble engagers.8-10,25-28 BATs combine the targeting precision of BiPEs with the intrinsic cytotoxic capacity of activated T cells, aiming to preserve potency while improving manufacturability and pharmacodynamic control.49-52
BATs are non-genetically modified T cells armed ex vivo with BiPEs, typically scFv-scFv constructs binding CD3ε and a TAA. After infusion, BiPE-armed T cells are bridged to tumor targets, inducing antigen-specific activation, immune synapse formation, and MHC-independent cytotoxicity26-28,49-52 (Fig 4). Transient surface arming enables controllable activity without genomic modification, potentially simplifying manufacturing relative to gene-modified products.49-52
BAT efficacy depends on stable immune synapse formation. BiPE-mediated CD3-TAA crosslinking enforces close contact and triggers spatial reorganization of signaling and adhesion components, including clustering of the T-cell receptor (TCR)/CD3 complex, recruitment of proximal kinases, and organization of central and peripheral supramolecular activation cluster (cSMAC/ pSMAC) structures supported by adhesion molecules.53-56 Downstream signaling drives Ca2+ influx, mitogen-activated
Fig 3. Structure and mechanism of action of bispecific protein engagers (BiPEs). BiPEs consist of two linked single-chain variable fragments (scFvs): one binds CD3ε on T cells and the other recognizes a tumor-associated antigen (TAA) on cancer cells. By simultaneously engaging both targets, BiPEs bridge T cells and tumor cells, promoting immune synapse formation, T-cell activation and proliferation, and perforin/ granzyme-mediated cytotoxicity in a major histocompatibility complex (MHC)–independent manner.
Fig 4. Structure and mechanism of action of bispecific protein engager (BiPE)–armed T cells (BATs). BATs are non-genetically modified T cells armed ex vivo with BiPEs, typically composed of scFv–scFv constructs that bind CD3ε on T cells and a tumor-associated antigen (TAA) on cancer cells. Following infusion, the BiPE molecules bridge BATs to tumor cells, promoting antigen-specific activation, immune synapse formation, perforin and granzyme release, and major histocompatibility complex (MHC)–independent tumor cell killing.
protein kinase activation, cytoskeletal remodeling, and microtubule-organizing center reorientation to deliver lytic granules.53-55 Perforin enables granzyme entry, notably granzyme B, to trigger apoptosis and cancer cell lysis (Fig 4); Fas/FasL can contribute in parallel.53-55,57
SiCORE-CIT has established BATs as a versatile platform targeting multiple antigens and immune checkpoints across hematologic and solid tumors. In multiple myeloma, anti-BCMA × anti-CD3 BATs promoted antigen-specific activation, proliferation, and cytotoxicity with robust effector cytokines and limited interleukin-6 (IL-6) induction.50 CD138-specific BATs showed strong and selective killing of CD138-positive myeloma cells with induction of cytolytic mediators including perforin, granzymes, soluble Fas ligand, and tumor necrosis factor-α (TNF-α), together with low levels of selected pro-inflammatory cytokines, supporting a potentially favorable safety profile.51 To overcome checkpoint-mediated suppression, anti-PD-L1 × anti-CD3 BATs efficiently lysed PD-L1-expressing breast cancer cells in two-dimensional and three-dimensional models and retained function after cryopreservation.49 In cholangiocarcinoma, A20/anti-CD3 BATs targeting integrin αvβ6 enhanced activation, proliferation, effector-
memory differentiation, and cytotoxicity, including against spheroids, supporting activity in complex tumor models.52 Chemotherapy can also modulate tumor immune susceptibility. For example, gemcitabine has been shown to upregulate PD-L1 expression in cholangiocarcinoma cells, creating an opportunity to exploit this adaptive change using anti-PD-L1 × anti-CD3 BiPEs to enhance T-cell-mediate cytotoxicity.58 Accordingly, BATs can be effectively integrated with chemotherapy. Combination strategies may leverage therapy-induced PD-L1 upregulation: for instance, anti-PD-L1 × anti-CD3 BATs combined with low-dose bortezomib demonstrated enhanced cytotoxic activity against multiple myeloma cells in preclinical models where bortezomib increased PD-L1 expression.59
BATs offer several potential advantages: (i) simplified manufacturing without genetic modification or vector production; (ii) shorter timelines and potentially lower cost using transient arming with relatively small amounts of BiPE; (iii) localized pharmacodynamic engagement with reduced dependence on continuous infusion; and
(iv) potential safety advantages via controllable arming density and transient activity.25-28,49-52
Preclinical BAT studies consistently show antigen-
specific cytotoxicity in hematologic and solid tumor models.49-52 Supportive translational evidence comes from BsAb-T trials, which demonstrate feasibility and a consistent absence of DLTs, with biological activity signals across indications.35-40
The immunosuppressive tumor microenvironment limits many immunotherapies. BATs may partially mitigate these barriers through localized, engager-mediated activation and by modular targeting, including checkpoint ligands such as PD-L1, to address heterogeneity and immune escape.26-28,49-52
Translation requires good manufacturing practice (GMP)-compliant BiPE production, validated arming conditions, and standardized potency/stability assays with defined release criteria.49-52 BATs share class risks of redirected T-cell activation, including CRS and less commonly neurotoxicity, and ASTCT grading provides standardized toxicity assessment.25 Antigen selection and affinity tuning remain essential to reduce on-target/ off-tumor toxicity.26-28
Compared with CAR T cells and continuous-infusion BiTE therapies, BATs may reduce complexity and improve accessibility, particularly if workflows become standardized and scalable.49-52
Next steps include dual- or multi-target BiPEs/BATs to reduce antigen escape, incorporation of costimulatory engagement or checkpoint blockade to enhance persistence and limit T-cell exhaustion, and development of off-the-shelf approaches, including allogeneic strategies, while addressing rejection, persistence, and safety.14,60-63 Beyond oncology, CD19- or BCMA-directed redirection strategies may be adaptable to selected antibody-mediated autoimmune diseases driven by pathogenic B cells or plasma cells, but will require stringent safety controls.64,65
CONCLUSION
BATs integrate bispecific targeting with T-cell cytotoxicity to enable MHC-independent tumor killing while potentially improving manufacturability and pharmacodynamic control relative to CAR T cells and soluble bispecific proteins. Accumulating preclinical evidence, supported by BsAb-T clinical experience, suggests BATs can deliver adaptable antitumor activity with a promising safety profile, but successful translation will require standardized GMP workflows, validated potency and safety testing, and rigorous clinical evaluation.35-40,49-52
The data that support the findings of this study are
available from the corresponding author upon reasonable request.
ACKNOWLEDGMENTS
The author sincerely thanks Miss Pucharee Songprakhon for preparing all the figures presented in this article. The author gratefully acknowledges the colleagues and staff members at the Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT) and the Division of Molecular Medicine (DMM), including Professor Chanitra Thuwajit, Associate Professor Peti Thuwajit, Associate Professor Mutita Junking, Dr. Jatuporn Sujjitjoon, Dr. Piriya Luangwattananun, Dr. Kamonlapat Supimon, Dr. Thanich Sangsuwannukul, Dr. Chalermchai Somboonpatarakun, Dr. Kwanpirom Suwanchiwasiri, Miss Nunghathai Sawasdee, Miss Pucharee Songprakhon, and Miss Thanyaporn Dechtawewat for their efforts and valuable contributions to the development and evaluation of the BAT platform. The author also sincerely appreciates the continuing collaboration and contributions of Professor Aussara Panya, Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand, and Assistant Professor Chutamart Thepmalee, Division of Biochemistry, School of Medical Sciences, University of Phayao, Phayao, Thailand. The SiCORE-CIT was financially supported by the Siriraj Research Fund (grant number R016737004).
DECLARATIONS
The author declares no conflicts of interest related to this review.
This review article did not receive any external funding.
The author declares that artificial intelligence (AI) tools were used to assist with literature searching and English-language editing, and to improve writing clarity. The author retains full responsibility for the originality, conceptualization, structure, scientific content, and integrity of the article.
REFERENCES
Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12(1):31-46.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
International Agency for Research on Cancer. Cancer Tomorrow. Lyon: International Agency for Research on Cancer; 2024.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64.
McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154-8.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230): 62-8.
June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-5.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-44.
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-87.
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-37.
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-44.
Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147-67.
Wutti-in Y, Sujjitjoon J, Sawasdee N, Kongkhla K, Choomee K, Phanthaphol N, et al. Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains. Front Oncol. 2022;11:802876.
Yuti P, Wutti-in Y, Sawasdee N, Kongkhla K, Phanthaphol N, Choomee K, et al. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1-mediated T cell inhibition. Int Immunopharmacol. 2022;113(Pt B):109442.
Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, et al. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B-cell maturation antigen in multiple myeloma. Biomed Pharmacother. 2023; 168:115691.
Sangsuwannukul T, Supimon K, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, et al. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. Int Immunopharmacol. 2020;89(Pt A):107069.
Supimon K, Sangsuwannukul T, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, et al. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci Rep. 2021;11(1):6276.
Luangwattananun P, Junking M, Sujjitjoon J, Wutti-in Y, Poungvarin N, Thuwajit C, et al. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen
expressed on breast cancer cells for adoptive T cell therapy. Breast Cancer Res Treat. 2021;186(1):25-36.
Somboonpatarakun C, Phanthaphol N, Suwanchiwasiri K, Ramwarungkura B, Yuti P, Poungvarin N, et al. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer. Int Immunopharmacol. 2024;129:111631.
Phanthaphol N, Somboonpatarakun C, Suwanchiwasiri K, Yuti P, Chieochansin T, Junking M, et al. Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin αvβ6 and secreting anti-PD-L1 scFv. J Transl Med. 2025;23:308.
Wutti-In Y, Luangwattananun P, Sawasdee N, Vongchan P, Yenchitsomanus PT, Panya A. Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer. Biomed Pharmacother. 2026 Feb;195:118967.
Somboonpatarakun C, Phanthaphol N, Suwanchiwasiri K, Ramwarungkura B, Yenchitsomanus PT, Junking M. Next-generation CAR T cells targeting integrin αvβ6 and PD-L1 to enhance immunotherapy for cholangiocarcinoma. Biomed Pharmacother. 2025; 193:118806.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-38.
Mack M, Riethmüller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A. 1995;92(15): 7021-5.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974-7.
Kontermann RE. Bispecific antibodies. Drug Discov Today. 2015;20(7):838-47.
Segal DM , Weiner GJ , Weiner LM . Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999;11(5):558-62.
Ridgway JBB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9(7):617-21.
Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011;108(27):11187-92.
Carter P. Bispecific human IgG by design. J Immunol Methods. 2001;248(1-2):7-15.
Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013;31(11):621-32.
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585-608.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, et al. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells. J Immunother Cancer. 2024;12(3):e008744.
Fadul CE, Thakur A, Kim J, Kassay-McAllister J, Schalk D, Lopes MB, et al. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide. J Neurooncol. 2024;166(2):321-30.
Lum LG, Al-Kadhimi Z, Deol A, Kondadasula V, Schalk D,
Tomaszewski E, et al. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2-negative (0-2+) metastatic breast cancer. J Immunother Cancer. 2021;9(6):e002194.
Vaishampayan UN, Thakur A, Chen W, Deol A, Patel M, Dobson K, et al. Phase II trial of pembrolizumab and anti-CD3
× anti-HER2 bispecific antibody armed activated T cells in metastatic castrate-resistant prostate cancer. Clin Cancer Res. 2023;29(1):122-32.
Lum LG, Thakur A, Choi M, Deol A, Kondadasula V, Schalk D, et al. Clinical and immune responses to anti-CD3 × anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) inpancreaticcancerpatients. Oncoimmunology. 2020;9(1):1773201.
Lum LG, Thakur A, Kondadasula SV, Al-Kadhimi Z, Deol A, Tomaszewski EN, et al. Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity. Biol Blood Marrow Transplant. 2016;22(5):869-78.
Goebeler ME, Bargou RC. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Cancer Treat Rev. 2016;49:63-76.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9): 836-47.
Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res. 2019;25(2):473-7.
U.S. Food and Drug Administration. FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia. U.S. Food and Drug Administration; 2018.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel J, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505.
Lesokhin AM, Tomasson MH, Arnulf B, Mikhael JR, Minnema MC, Krishnan A, et al. Elranatamab in patients with relapsed or refractory multiple myeloma. Nat Med. 2023;29(9):2259-67.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196-206.
Hassel JC, Piperno-Neumann S, Schankin C, Rutkowski P, Carvajal RD, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24): 2256-66.
Luangwattananun P, Sangsuwannukul T, Supimon K, Thuwajit C, Chieochansin T, Sa-nguanraksa D, et al. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1. Int Immunopharmacol. 2023;124:111012.
Supimon K, Sangsuwannukul T, Luangwattananun P,
Yenchitsomanus PT. Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells. Int Immunopharmacol. 2024;143(Pt 2):113480.
Songprakhon P, Luangwattananun P, Choomee K, Sawasdee N, Somboonpatarakun C, Chieochansin T, et al. CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells. Int Immunopharmacol. 2026;174:116295.
Suwanchiwasiri K, Somboonpatarakun C, Phanthaphol N, Yuti P, Chieochansin T, Junking M, et al. Bispecific T cell engager-armed T cells targeting integrin αvβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma. Biomed Pharmacother. 2024;175:116718.
Dustin ML, Long EO. Cytotoxic immunological synapses. Immunol Rev. 2010;235(1):24-34.
Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol. 2007;23:495-517.
Huse M. Mechanical forces in the immune system. Nat Rev Immunol. 2017;17(11):679-90.
Dustin ML. The immunological synapse. Cancer Immunol Res. 2014;2(11):1023-33.
Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15(6):388-400.
Wathikthinnakon M, Sittithumcharee G, Chen S, Prasopporn S, Choomee K, Chieochansin T, et al. Gemcitabine and anti-PD-L1
× anti-CD3 bispecific T-cell engager synergistically enhance T-cell cytotoxicity against cholangiocarcinoma cells. Sci Rep. 2022; 12(1):6154.
Sawasdee N, Songprakhon P, Luangwattananun P, Rujirachaivej P, Yuti P, Yenchitsomanus PT. Low-dose bortezomib enhances the cytotoxicity of anti-PD-L1 × anti-CD3 bispecific engager-armed T cells against multiple myeloma cells. Biomed Pharmacother. 2025;184:117878.
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-99.
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185-99.
Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566-81.
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503-10.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124-32.
Vu T, Gwathmey K, Benatar M, Cutter G, Claussen G, Burns TM, et al. BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2026 Jan 9. doi: 10.1038/ s41591-025-04171-y.